| CEO Name | Rick DeLuca |
| Nationality | United States |
| Net Worth Estimation | $40 million |
Rick DeLuca's estimated net worth of around $40 million stems from his high-ranking executive roles at Merck Animal Health and other pharmaceutical companies, combined with substantial compensation packages, stock options, and long-term incentives. His industry expertise and leadership in global animal health business have significantly contributed to his accumulated wealth.
Rick DeLuca, CEO of Intervet (now part of Merck Animal Health), has an estimated net worth of $40,000,000, which is 58.8% of the maximum and 4,000% of the minimum estimated CEO net worth in the veterinary business category. His net worth places him well above the category's minimum and close to the upper range.
Business Category: Veterinary
Minimum Net Worth (estimation): 1000000 USD
Maximum Net Worth (estimation): 70000000 USD
Rick DeLuca Performance in Intervet (Now part of Merck Animal Health)
Rick DeLuca, CEO of Intervet (now Merck Animal Health), demonstrated strategic leadership by driving innovation and operational excellence in animal health pharmaceuticals. His decision-making focused on expanding global market reach and integrating cutting-edge research to enhance product pipelines. Under DeLuca's leadership, the company experienced significant growth and strengthened its position as a leader in veterinary health solutions.
Latest News
Merck Animal Health (formerly Intervet) advances parasite prevention under CEO Raul Kohan.
Merck Animal Health, previously known as Intervet/Schering-Plough Animal Health, rebranded in 2011 under CEO Raul Kohan, continuing innovation in veterinary parasiticide products like BRAVECTO(r). The company emphasizes R&D and global market leadership in animal health with sustained growth focus.
Source: http://www.merck.com/news/merck-announces-new-name-for-its-animal-health-division/